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Aim: This study compared the dosimetric impact between prostate IMRT and VMAT due to
patient’s weight loss.
Background: Dosimetric variation due to change of patient’s body contour is difﬁcult to predict
in  prostate IMRT and VMAT, since a large number of small and irregular segmental ﬁelds is
used in the delivery.
Materials and methods: Five patients with prostate volumes ranging from 32.0 to 86.5 cm3
and a heterogeneous pelvis phantom were used for prostate IMRT and VMAT  plans using
the same set of dose–volume constraints. Doses in IMRT and VMAT plans were recalculated
with  the patient’s and phantom’s body contour reduced by 0.5–2 cm to mimic size reduction.
Dose coverage/criteria of the PTV and CTV and critical organs (rectum, bladder and femoral
heads) were compared between IMRT and VMAT.
Results: In IMRT plans, increases of the D99% for the PTV and CTV were equal to 4.0 ± 0.1%
per  cm of reduced depth, which were higher than those in VMAT plans (2.7 ± 0.24% per cm).
Moreover, increases of the D30% of the rectum and bladder per reduced depth in IMRT plans
(4.0  ± 0.2% per cm and 3.5 ± 0.5% per cm) were higher than those of VMAT (2.2 ± 0.2% per cm
and  2.0 ± 0.6% per cm). This was also true for the increase of the D5% for the right femoral
head in a patient or phantom with size reduction due to weight loss.
Conclusions: VMAT would be preferred to IMRT in prostate radiotherapy, when a patient has
potential to suffer from weight loss during the treatment.
©  2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All∗ Corresponding author at: Radiation Medicine Program, Princess Marga
2M9,  Canada. Tel.: +1 416 946 4501; fax: +1 416 946 6566.
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.  Background
n prostate radiotherapy, multi-beam step-and-shoot inten-
ity modulated radiotherapy (IMRT) has in many  centers been
eplaced by volumetric modulated arc therapy (VMAT), which
as a shorter delivery time and smaller monitor unit (MU).1–5
ome studies in patient dosimetry between prostate IMRT
nd VMAT  show that VMAT  is a more  efﬁcient dose deliv-
ry technique than IMRT  as it has good target coverage and
pares critical organs, such as rectum, bladder and femoral
eads.4,6–13 However, unlike step-and-shoot IMRT  in which
he gantry is static for each beam angle, VMAT interplays
he multi-leaf collimator (MLC) shapes, MLC speed, dose rate
nd gantry speed in a single or multiple photon arcs for dose
elivery.8,14–18 This complex dose delivery technique results
n a difﬁcult MU calculation, almost impossible to be done
anually using the basic dose ratio methods.19–21
Patient size reduction during radiotherapy was found and
tudied in head-and-neck cancer.22–24 However, there is lit-
le study related to the dosimetric impact due to the change
f body contour. Although the weight loss issue in prostate
ancer is less signiﬁcant than head-and-neck, it sometimes
ccurs during radiotherapy.25,26 This is mainly due to the side
ffects of dehydration and/or loss of appetite during the course
f treatment. This size reduction used to reduce the patient’s
ody contour while the bone anatomy remains unchanged.
he result of dosimetric change due to reduced size or depth
f patient is the increase of delivered dose to the prostate
lanning and clinical target volume (PTV and CTV). Moreover,
 reduction in the patient size increases doses in the rec-
um, bladder and femoral heads.27 The dosimetric impacts on
he targets and critical organs with regards to reduced depth
epend on the dose delivery technique.28
It has been proven that prostate VMAT has comparable
TV/CTV coverage and sparing of critical organs as IMRT12,13;
owever, there remains no study on the dosimetric compari-
on between IMRT  and VMAT  regarding patient size reduction
n prostate radiotherapy.
.  Aim
n the prostate treatment plan, dose–volume constraints for
he target and critical organs are used in the plan optimiza-
ion based on objective function.29,30 Dose distributions on
he target and critical organs are different for prostate plans
enerated by IMRT  and VMAT  technique using the same set
f dose–volume constraints, because IMRT  and VMAT  use
ifferent parameters of gantry angle, dose rate and MLC
hapes in the plan optimization. It is therefore, worthwhile
o compare the dose coverage due to patient size reduc-
ion between IMRT  and VMAT.  In this study, IMRT and VMAT
rostate plans were generated for patients and a heteroge-
eous pelvis phantom using the same prescription dose and
ame set of dose–volume constraints for target and criti-
al organs. Changes to Dose–Volume Histograms (DVHs) and
ose criteria for the PTV, CTV, rectum, bladder and femoral
eads with respect to the patient size reduction were com-
ared between IMRT  and VMAT.  To our knowledge, this istherapy 1 8 ( 2 0 1 3 ) 272–278 273
the ﬁrst investigation on the dosimetric comparisons between
prostate IMRT and VMAT due to patient’s weight loss.
3.  Materials  and  methods
3.1.  Patient  and  phantom
In this study, IMRT and VMAT prostate plans were created for
ﬁve patients in a group of 30, covering a range of prostate target
volumes from 32.0 cm3 to 86.5 cm3 at the Grand River Hospital.
The ﬁve patients represented the maximum, medium, mini-
mum, halfway between maximum and medium and halfway
between medium and minimum prostate volumes in the
patient group. On the other hand, a heterogeneous virtual
human male pelvis phantom (CIRS 801-P-F) was used for the
IMRT  and VMAT plans. The phantom was scanned as if it were
a patient using the same CT-SIM scanner and protocol. The
PTV, rectum, bladder, right and left femoral head volume of
the phantom are 72.4, 37.4, 59.5, 131.8 and 124.1 cm3, respec-
tively. The PTV, CTV, rectum, bladder and femoral heads of the
prostate patients and phantom were contoured by the same
person using their computed tomography (CT) image  sets. The
CTV was equal to the prostate volume. The PTV was created
by expanding the CTV with a 1 cm margin, except in the poste-
rior direction where a 0.7 cm was used. Patient immobilization
used a parallel-leg immobilizer and the patient was ensured to
have a comfortably full bladder and empty rectum in the treat-
ment. All patients were scanned by the Siemens SOMATOM
Sensation Open CT-simulator with the same protocol. Dosi-
metric veriﬁcations of VMAT for patients and the phantom
were done using the ArcCHECK 4D cylindrical detector array.31
3.2.  IMRT  and  VMAT  treatment  planning
All prostate plans were created for patients and phantom in
the supine position, using a 6 MV  photon beam from a Var-
ian 21 EX linear accelerator (Varian Medical System, Palo Alto,
CA). A 120-leaf Millennium MLC system was used to generate
ﬁeld segments for the beam intensity modulation. Treatment
plans were created using the Eclipse treatment planning sys-
tem (version 8.5, Varian Medical System, Palo Alto, CA). The
prescribed dose was 78 Gy in 39 fractions (2 Gy per fraction).
The dose was prescribed to the median dose (D50%) of the PTV
as normalization, and the anisotropic analytical algorithm
was used in dose calculations with dose grid resolution set
to 0.25 cm.  For IMRT prostate plan, a seven-beam technique
was used with beam angles equal to 40, 80, 110, 250, 280, 310
and 355 degrees.32 The dose–volume constraints for the tar-
get volumes and critical organs for the inverse planning are
shown in Table 1. These constraints were parameters in the
optimization cost function. The speciﬁc fraction of volume
based on the function is allowed to exceed the prescribed dose
limit in the case of a critical organ or target, to be less than
the prescribed value.32,33 The same set of constraints (Table 1)
and prescription dose were used for the VMAT  prostate plans,
in the optimization. The dose delivery of VMAT  was carried
out using a single 360 degree photon arc with inverse plan
optimized by the Eclipse RapidArc algorithm (Varian Medical
System, Palo Alto, CA).
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Table 1 – Dose–volume constraints of the CTV, PTV,
rectum, bladder, left and right femoral head used in the
7-beam IMRT  and VMAT  prostate plan.
Volume of
interest
Dose–volume control point (Gy)
CTV D99% ≥ 78
PTV D99% ≥ 74.1
PTV Maximum dose to 1 cm3 ≤ 81.9
Rectum D50% ≤ 60; D35% ≤ 65;
D25% ≤ 70 Gy; D15% ≤ 75
Bladder D50% ≤ 65; D35% ≤ 70;
D25% ≤ 75 Gy; D15% ≤ 80
Left and right D5% ≤ 54.3
criteria per reduced depth in Figs. 3 and 4 were determined for
patients and the phantom using linear regression ﬁtting withfemoral head
3.3.  Patient  and  phantom  size  reduction
The contraction of body contours due to size reduction was
mimicked by decreasing the body contour with reduced
depths (0.5–2 cm)  in the anterior, and both lateral directions
of the patient and phantom based on our clinical experience.
The original normal tissue outside the contracted body con-
tour was replaced by air. Fig. 1(a)–(c) shows the heterogeneous
phantom’s anatomy in the axial, coronal and sagittal view,
after the body contour was contracted by a reduced depth
of 1 cm,  respectively. Reduced depths of 0.5, 1, 1.5 and 2 cm
were used in the patient and phantom size reduction for com-
parison. Intensity modulated radiotherapy and VMAT  prostate
plans of zero reduced depth were transferred to the modiﬁed
patient’s and phantom’s anatomy with reduced depth for the
dose recalculation. Dose–Volume Histogram and dose criteria
Fig. 1 – CT images of the (a) axial, (b) coronal and (c) sagittal view
the PTV, CTV (prostate), bladder, rectum and femoral heads. The
right direction) with the excluded patient body (normal tissue) reiotherapy 1 8 ( 2 0 1 3 ) 272–278
for the target and critical organs were determined with differ-
ent reduced depths for each plan.
4.  Results
Dose–Volume Histograms of the PTV, rectum, bladder and
right femoral head for the patient with the medium prostate
volume (48.4 cm3) are shown in Fig. 2(a–d), respectively. The
reduced depths in Fig. 2 are equal to 0, 1 and 2 cm using IMRT
and VMAT technique. All dose criteria in IMRT  and VMAT
plan with zero reduced depth satisﬁed the dose–volume con-
straints in Table 1. Fig. 3(a) and (b) shows increases in the
D99% of the PTV and CTV with increased reduced depth for the
IMRT and VMAT plans for patients and the phantom. All D99%
in Fig. 3 calculations were based on the reduced depth and
were normalized to those calculated using the zero reduced
depth for comparison. For critical organs, increases in the
D30% of the rectum and bladder based on the patient and
phantom size reductions are shown in Fig. 4(a) and (b), respec-
tively. Increases in the D5% of the right femoral head with an
increase in reduced depth are shown in Fig. 4(c). Due  to the
symmetry of the right and left femoral head in patient and
phantom anatomy, only dose criteria of the right femoral head
are shown in this study. All D30% and D5% in Fig. 4 were nor-
malized to those calculated based on a zero reduced depth
for comparison. Slopes representing changes of dose–volumecoefﬁcient of determination value R equal to 0.99. It should
be noted that all results of dose criteria in this study were
s for the heterogeneous pelvis phantom, with contours of
 body contour was reduced by 1 cm depth (anterior, left and
placed by air.
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Fig. 2 – DVHs of the (a) PTV, (b) rectum, (c) bladder and (d) right femoral head in prostate IMRT  (solid lines) and VMAT
(broken lines) plans for the patient with medium prostate volume (48.4 cm3). Depths of the body contours were reduced by
0, 1 and 2 cm.
Fig. 3 – Relationships between changes of the D99% and size reduction of patients and the phantom in term of the reduced
depth for the (a) PTV, and (b) CTV of patients in IMRT  and VMAT.
276  reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) 272–278
Fig. 4 – Relationships between changes of the D30% and size reduction of patients and the phantom in term of the reduced
depth for the (a) rectum, and (b) bladder in IMRT  and VMAT.  (c) shows changes of the D5% of the right femoral head varying
with the reduced depth for patients and the phantom.
based on the treatment dose evaluation criteria in our previous
work.32
5.  Discussion
Fig. 2(a) shows DVHs of the PTV for the patient with medium
prostate volume (48.4 cm3) planned by IMRT  and VMAT tech-
nique, using reduced depths of 0, 1 and 2 cm.  In Fig. 2(a),
maximum doses of dose–volume curves (IMRT and VMAT)
move toward the positive x-axis with an increase in the
reduced depth. The maximum dose increases because the
reduced depth results in an increase of dose at the PTV. Such
dose enhancements due to a decrease in beam attenuation
can also be observed in critical organs, such as rectum, bladder
and femoral head, as shown in Fig. 2(b–d), respectively. Simi-
lar dosimetric results can be found in IMRT  and VMAT  plans
for the phantom. These variations in DVHs for the target and
critical organs may lead to changed dose criteria higher than
the planned values, which may not be acceptable in the treat-
ment plan evaluation. Therefore, more  detailed examinations
concerning variations in dose criteria with the reduced depths
in IMRT  and VMAT  were carried out.Fig. 3(a) and (b) shows changes in the D99% of the PTV and
CTV with the reduced depth for patients and the phantom
planned per IMRT  and VMAT. Fig. 3(a) and (b) indicates that
the D99% of the PTV and CTV increase with the reduced depth
from 0 to 2 cm,  which agrees with the relationship between
the DVH and reduced depth as shown in Fig. 2(a). For the
PTV and CTV, variations in the D99% with the reduced depth
were found to be independent to the patient’s prostate volume
in IMRT  and VMAT plans (Fig. 3(a) and (b)). From the patient
results, increases in the D99% for the PTV and CTV in IMRT
were both equal to 4.0 ± 0.1% per cm of the reduced depth.
These increases in the D99% are higher than those of 2.7 ± 0.2%
per cm in VMAT.  It is found that the increases in the D99% for
the PTV and CTV for the phantom were 4.06 and 2.79% per
cm,  which are within the range of patient results. It should be
noted that changes in the D99% are similar for the PTV and
CTV, because of the small margin difference of 0.5–1 cm,  and
have the same isocenter. Fig. 3 indicates that increase in the
D99% was more  signiﬁcant in prostate IMRT than VMAT under
a patient or phantom size reduction.
For the critical organs, Fig. 4(a) indicates increases in the
D30% of the rectum with an increase in the reduced depth
in IMRT and VMAT. Again, the D30% increases more  for IMRT
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4.0 ± 0.2% per cm for patient and 4.20% per cm for phantom)
han VMAT  (2.2 ± 0.2% per cm for patient and 2.34% per cm for
hantom). For the bladder, increases in the D30% due to the
educed depth are slightly less than the rectum. The changes
f D30% are 3.5 ± 0.5% per cm for IMRT  and 2.0 ± 0.6% per cm
or VMAT  for patients, and 3.79% per cm for the IMRT and
.55% per cm for the phantom (within the range of patient
esults) according to Fig. 4(b). This smaller change of the D30%
f the bladder compared with the rectum is based on the
osition of bladder further away from the isocenter compared
ith the rectum. Fig. 4(c) shows increases in the D5% of the
ight femoral head with the reduced depth for patients and
hantom. From the patient results, increases in the D5% are
.7 ± 0.1% per cm for IMRT  and 3.3 ± 0.1% per cm for VMAT.
hese agree to the phantom results of D5% increased 3.71%
er cm for IMRT  and 3.32% per cm for VMAT. The difference
n the D5% between IMRT  and VMAT  was smaller than those
f the D30% for the rectum and bladder. This may be due to
he depth of the femoral head from the body contour being
maller than those of the rectum and bladder. Similar to the
TV and CTV, dose criteria of critical organs increased more
igniﬁcantly in IMRT than VMAT,  when patient or phantom
ize reduction occurs during the treatment. To estimate dosi-
etric changes of the target and critical organs in greater
etail, there is a need to construct a more  delicate deformation
odel in future. This will be carried out based on the cone-
eam CT image  set obtained from patients who lost weight
uring their radiotherapy courses.
.  Conclusions
t was concluded that for prostate patient having high poten-
ial of weight loss during radiotherapy, VMAT would be
referred to IMRT  regarding the dosimetric changes in the
arget and critical organs under a patient size reduction.
he dosimetry estimation presented in this study using both
atient and phantom present important data for the radia-
ion oncology staff to justify whether a CT rescan is necessary
hen a patient experiences weight loss during treatment. In
ddition, it is important to know if the patient’s weight loss is
olerable (i.e. the changed dose accepted by the treatment dose
valuation criteria), how the doses and dose criteria would
hange as per change of the patient’s size in prostate IMRT
nd VMAT.
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